Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on August 3, 2023, to announce its financial and operating results for the second quarter ended June 30, 2023. The primary purpose of this filing is to furnish the associated press release, which contains the detailed results and operational updates. Investors should refer to the press release (Exhibit 99.1) for the most comprehensive information regarding REGN's performance during the quarter.
Key Highlights
- 1Regeneron announced its Q2 2023 financial and operating results via a press release filed as Exhibit 99.1.
- 2The filing provides details on the company's performance for the quarter ended June 30, 2023.
- 3Investors are directed to the furnished press release for specific financial figures and operational insights.
- 4The report is an 8-K filing, indicating a material event, which in this case is the release of quarterly earnings.
- 5The press release contains information that is being furnished, not deemed 'filed' under Section 18 of the Securities Exchange Act, limiting its liability implications.
- 6The filing includes the Interactive Data File (XBRL) for enhanced data accessibility.